Liver transplantation increases R0 resection and survival of patients with a non-disseminated unresectable Klatskin tumour

Ricardo Robles, a, * Pascual Parrilla, a Pablo Ramírez, a Francisco Sánchez-Bueno, a Caridad Marín, a Patricia Pastor, a José Antonio Pons, b Francisco Acosta, c Domingo Pérez-Flores, d and Jesús de La Peña Morales e

a Unidad de Cirugía Hepática y Trasplante Hepático, Departamento de Cirugía, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
b Sección de Aparato Digestivo, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
c Servicio de Anestesia, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
d Facultad de Medicina, Universidad de Murcia, Espinardo, Murcia, Spain
e Servicio de Anatomía Patológica, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain

ARTICLE INFORMATION

Article history:
Received August 2, 2009
Accepted November 10, 2009
Online January 13, 2010

Keywords:
Liver tumours
Klatskin tumour
Liver transplant
Liver surgery

ABSTRACT

Introduction: There are no established indications for liver transplant (LT) in patients with a Klatskin tumour (KT) due to the differences in the published results.

Objective: To report on our patients who have non-disseminated unresectable KT and who were given a LT, and to compare results with those of patients who have had tumour resection and those who have not.

Patients and method: We have treated 75 patients diagnosed with KT. The mean age was 62 (11) years (range, 38–88 years) and 50 were males (66%). Twenty patients were inoperable. Of the 55 patients who underwent surgery: tumour resection (TR) was performed in 29 cases; there was no tumour dissemination in 11 unresectable cases and therefore these patients were added to the LT waiting list and the remaining 15 unresectable cases had tumour dissemination and remained on palliative treatment.

Results: In the LT group there was no postoperative mortality (during the first month) and the survival rate was 95%, 59%, and 36% with a disease-free survival of 75%, 40%, and 20%; whereas the patients given KT had a survival rate of 80%, 52%, and 38% at 1, 3, and 5 years, with a disease-free survival of 65%, 35%, and 19%, without any differences compared to the LT group. Patients with unresectable tumour left on palliative therapy had a lower survival than the unresectable who underwent LT (P<.001).

Conclusions: In patients with non-disseminated unresectable KT, LT has a similar survival to that obtained in cases with resectable R0 liver resection. LT improves the survival rate achieved using palliative treatment in patients with non-disseminated unresectable KT.

© 2009 AEC. Published by Elsevier España, S.L. All rights reserved.
Introduction

The most accepted treatment for hilar cholangiocarcinoma (Klatskin tumour, KT) is R0 liver resection, which presents a 5-year survival for between 20% and 45% of cases.1-16 In inoperable patients, survival is 0 to 5 years, and in patients whose tumour is unresectable without dissemination (due to the extension of the tumour to the intra-hepatic biliary radicals, bilaterally), the prognosis is similar to inoperable patients. In these cases, some authors propose a liver transplantation (LT),17-26 although some groups considered this contraindicated due to the shortage of organs. In 1993, the Mayo Clinic group launched a chemo-radiotherapy protocol prior to LT in these same patients, presenting good results after 5 years.27-31

Our goal is to present the results obtained in our patients with KT, which in the course of the laparotomy were considered unresectable due to infiltration of the intra-hepatic bile duct in the absence of extra-hepatic disease, who subsequently received LT. The results of this group of patients are compared with those obtained in patients who could undergo a resection without LT and with those of patients without resection either because they were inoperable or because the disease was found to be disseminated during the laparotomy.

Patients and method

From May 1988 (start date of our LT program) until October 2008, we treated 75 patients with the diagnosis of KT. The median age was 62 (11) years (range, 38-88 years) and 50 were males (66%). In 69 patients, the symptoms were secondary to cholestasis and the total bilirubin (TB) level was 14 (11) mg/dL (range, 5-44), in 6 cases (8%) there was no jaundice and one dissociated cholestasis was found in the analytical tests. Eleven patients (14%) presented renal failure with creatinine levels greater than 3. All patients underwent ultrasound and triple-phase hepatic CT, looking for dilated intrahepatic biliary radicals, a tumour mass in the porta, liver metastases, retroperitoneal or hepatic hilum lymphadenopathy and portal or arterial invasion. Since 1998 we have been performing systematic cholangio-MR (50 patients). In 63 patients (84%), all with TB levels above 10 ng/mL, a percutaneous transhepatic cholangiography was performed by placing an external supratumoural intrahepatic biliary drain to avoid manipulating the tumour. When we considered the patient to be inoperable,32 we inserted an internal-external guide or permanent transtumoural prosthesis.

To determine the location of the tumour, we used the classification of Bismuth-Corlette33: five cases of type I (6.6%), 4 cases type II (5.3%), 22 type III cases (29.3%), and 44 type IV cases (58.6%). For the final staging of the tumour, we used the TNM classification of the international union against cancer (UICC).34

Twenty patients were considered inoperable (inoperable criteria in Table 1). Tumour resection (TR) was performed in 29 of the 55 patients who underwent surgery, 11 were unresectable tumours without dissemination, and they were therefore included on the waiting list for LT, and 15 patients with unresectable tumours with dissemination were given palliative treatment (Table 1).
The group of patients who did not undergo tumour resection was composed of 35 patients (20 inoperable and 15 unresectable), and the group of patients whose tumour could be resected consisted of 40 patients: twenty-nine with TR and 11 with LT.

Statistical method. Rates and survival curves were calculated using the Kaplan-Meier method and log-rank test. Survival data of each group are summarized by their survival rates at 1, 3, and 5 years with 95% confidence intervals. Potential prognostic factors for survival were evaluated with the Cox proportional hazards regression model. We present the results of the prognostic factors for survival, selected with the risk ratio for each category (odds ratio) and its 95% confidence interval. A P value of less than .05 was considered statistically significant.

**Results**

**Patients without tumour resection (n=35)**

In inoperable cases (n=20), half-life was 6 (2) months (range, 1-14 months). In the first month of admission 7 patients died (35%) from complications and the 13 remaining patients died of advanced neoplastic disease. No patient received postoperative chemotherapy or radiotherapy. There were no postoperative mortalities (first month). R0 resection was achieved in all cases. The half-life was 60 (17) months (range, 12-122 months) and 7 patients died in follow-up, all from tumour disease: five recurring abdominal tumours (at 12, 16, 19, 43, and 46 months), one from lung metastases (12 months) and one for a de novo abdominal tumour (undifferentiated tumour with a lymphomatous origin at 122 months). Four patients lived for 96, 72, 39, and 12 months, respectively.

**TR group (n=29).** Four of them (13%) underwent local tumour resection, all Bismuth I, with complete resection of the bile duct and Roux-Y hepaticojejunostomy (Table 2). In 25 cases (87%) hepatectomy was associated with resection of the caudate: left in 18 cases, right in 4 cases, and broadened right in 3 cases. In all cases, reconstruction was performed on 2 or 3 biliary radicals, all guided. In all patients, lymphadenectomy of the hepatic hilum and the celiac axis was associated, and in 2 cases, retroperitoneal lymphadenectomy. Seven patients had hilar lymph node invasion, 3 patients had retroperitoneal lymph node invasion, and 2 patients had liver metastases in the left lobe that was resected (Table 2). In 5 patients, with invasion of the portal vein, resection was performed of the entire circumference of the portal vein with end-to-end anastomosis or partial resection with its removal. Five patients received postoperative chemotherapy (5-fluorouracil) plus external radiotherapy. The half-life was 49 (8) months (range, 1-78 months). One patient (3.4%) died at 2 months due to biliary sepsis and multi-organ failure.

At follow up, 13 patients have died of tumour recurrence (44%) (4 with local tumour resection and 9 of the 25 remaining patients with liver resection). Therefore, 16 patients are still alive, 2 with disease relapse in current treatment with chemotherapy.

**Comparisons between groups**

In the LT group, the mean age was lower (P=.02), the TB was higher (P=.003), and the Bismuth IV was more frequent (P=.05) than in the TR group (Table 2).

Inoperable patients (n=20) had a 1-year survival rate of 27% and 0% at 2 years. Those unresectable patients with dissemination who did not receive LT (n=15) had a survival rate of 28% per year and 12% at 2 years, much lower than that obtained for unresectable patients receiving LT (P=.001). Patients with LT had a survival of 95%, 59%, and 36% with a
disease-free survival of 75%, 40%, and 20%, and patients with TR (n=29) had a survival of 80%, 52%, and 38% at 1, 3, and 5 years with a disease-free survival of 65%, 35%, and 19%, without significant differences regarding the LT group (Figure).

Prognostic factors for survival in resected patients (n=40) (Table 3)

Bismuth I and II patients (P<.005) and vascular invasion (P<.02) were factors for a poor prognosis of survival (the Bismuth I-II, possibly related to the performance of local tumour resection). Advanced stages were near the statistical significance of a poor prognosis because they showed worse survival at 5 years than early cases (19% vs 38%), scirrhous histologic types (23% vs 58%), and peri-neural invasion (31% vs 50%).

Discussion

Most authors consider the LT contraindicated in KT due to poor published results, despite getting more resecability, which in our series was 100%, while the number found in the series by Hidalgo et al was 75%. Some authors, by seeking a higher R0 resection, associate the DPC to the LT, and even Starlz et al extend the resection to adjacent organs (cluster transplantation).

The poor results are associated with high tumour relapse, which occurs between 56% and 96% of patients usually in the abdomen, which is related to the immunosupression that favours the spread of the tumour remains that may go undetected. These results are also related with a poor selection of patients, as LT was indicated for tumours that

<table>
<thead>
<tr>
<th>Variables</th>
<th>Resection (n=29)</th>
<th>Transplant (n=1)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>64 (10)</td>
<td>51 (10)</td>
<td>.02</td>
</tr>
<tr>
<td>Sex: males</td>
<td>14 (48%)</td>
<td>10 (91%)</td>
<td>.036</td>
</tr>
<tr>
<td>TB</td>
<td>6.9 (6.3)</td>
<td>12.8 (4)</td>
<td>.003</td>
</tr>
<tr>
<td>Ca 19/9</td>
<td>382 (197)</td>
<td>371 (197)</td>
<td>.385</td>
</tr>
<tr>
<td>Renal failure</td>
<td>1 (3.4%)</td>
<td>1 (9%)</td>
<td>.792</td>
</tr>
<tr>
<td>Bismuth</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>4 (13.8%)</td>
<td>1 (9%)</td>
<td>.05</td>
</tr>
<tr>
<td>II</td>
<td>1 (3.4%)</td>
<td>10 (91%)</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>17 (58.6%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>7 (24%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LM</td>
<td>2 (6.8%)</td>
<td>1 (9%)</td>
<td>.527</td>
</tr>
<tr>
<td>TNM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1N0M0</td>
<td>2 (6.9%)</td>
<td>1 (9%)</td>
<td></td>
</tr>
<tr>
<td>T2N0M0</td>
<td>6 (20.6%)</td>
<td>3 (27%)</td>
<td>.380</td>
</tr>
<tr>
<td>T3N0M0</td>
<td>11 (37.9%)</td>
<td>4 (6%)</td>
<td></td>
</tr>
<tr>
<td>T2N1M0</td>
<td>1 (3.4%)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>T3N1M0</td>
<td>4 (13.8%)</td>
<td>2 (18%)</td>
<td></td>
</tr>
<tr>
<td>T3N2M0</td>
<td>3 (10.3%)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>T3N0M1</td>
<td>0</td>
<td>1 (9%)</td>
<td>.527</td>
</tr>
<tr>
<td>T3N1M1</td>
<td>1 (3.4%)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>T3N2M1</td>
<td>1 (3.4%)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Stages</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-II</td>
<td>8 (27%)</td>
<td>4 (36%)</td>
<td>.391</td>
</tr>
<tr>
<td>III-V</td>
<td>21 (73%)</td>
<td>7 (64%)</td>
<td></td>
</tr>
<tr>
<td>Histological type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scirrhous</td>
<td>22 (75%)</td>
<td>10 (91%)</td>
<td>.269</td>
</tr>
<tr>
<td>Non scirrhous</td>
<td>7 (25%)</td>
<td>1 (9%)</td>
<td></td>
</tr>
<tr>
<td>Invasive margin</td>
<td>5 (17%)</td>
<td>0%</td>
<td>.127</td>
</tr>
<tr>
<td>Vascular invasion</td>
<td>5 (17%)</td>
<td>1 (9%)</td>
<td>.475</td>
</tr>
<tr>
<td>Parenchyma invasion</td>
<td>20 (68%)</td>
<td>7 (63%)</td>
<td>.497</td>
</tr>
<tr>
<td>Lymph node invasion</td>
<td>10 (34%)</td>
<td>2 (18%)</td>
<td>.285</td>
</tr>
<tr>
<td>Peri-neural invasion</td>
<td>20 (68%)</td>
<td>10 (91%)</td>
<td>.05</td>
</tr>
<tr>
<td>Adjuvant treatment</td>
<td>5 (17%)</td>
<td>0%</td>
<td>.182</td>
</tr>
<tr>
<td>Mortality 1st month</td>
<td>1 (3.4%)</td>
<td>0%</td>
<td>.358</td>
</tr>
<tr>
<td>Survival at 1, 3, and 5 years (DFS)</td>
<td>80%, 52%, and 38% (65%, 35%, and 19%)</td>
<td>95%, 59%, and 36% (75%, 40%, and 20%)</td>
<td>.727</td>
</tr>
</tbody>
</table>

DFS indicates disease-free survival; LM, liver metastases; TB, total bilirubin.
were considered non-disseminated, however in the explant histological study there was ganglion, arterial and portal invasion as well as peritoneal dissemination. As a result, in the series of LT in KT, 5-year survival ranges between 0% and 38%\textsuperscript{21-26,35-37} and, with greater intensity (cluster transplantation), it does not exceed 38%.\textsuperscript{19,20}

Despite the poor results, it was demonstrated that some patients with HT showed prolonged survival. Therefore, in the Spanish series\textsuperscript{35} with a postoperative mortality of 8.3%, we collected 36 HT from KT with a 5-year survival of 30%. However, in the early stages (stages I-II) the rate was 47%, whereas in stages III-IV the rate was only 15%, results similar to those obtained in this study. In a similar study, Kaiser et al\textsuperscript{38} (experience in Germany) reported 47 patients transplanted from KT, with a higher postoperative mortality (20%), and a survival rate of 22% at 5 years. When the selection criteria were more strict (since 1998) survival of 15 transplanted patients was 48% at 5 years (\(P<.014\)).

Some series compare the resection with non-neoadjuvant LT. Hidalgo et al\textsuperscript{37} collected 106 patients with KT, resection was achieved in 44 cases and LT was performed in 12 cases. There were no differences in sex, early stages, tumour size, lymph node invasion (7 of LT group were N1), degree of differentiation, peri-neural invasion, and vascular invasion when comparing resection and LT. There were no differences in survival rates at 5 years (28% with resection compared with 20% with LT). As in our series, patients who received LT were younger than patients with resection (\(P<.012\)). Stage III-IV were factors of poor prognosis along with R1-2 resections, presence of lymph node invasion, the presence of liver metastases, undifferentiated tumours and vascular invasion. Similarly, Iwatsuki et al\textsuperscript{39} and us\textsuperscript{36} did not find survival rate differences between LT and TR with liver resection.

At present there are data in the medical literature indicating that non-disseminated unresectable KT is a good indication for LT. In 1993, the Mayo Clinic initiated a protocol\textsuperscript{27-31} of neoadjuvant treatment with external radiotherapy, chemotherapy and internal radiation therapy in cholangiocarcinomas I and II of the TNM classification, which were unresectable by a first laparotomy. Two months after finishing radiotherapy, a second exploratory laparotomy was performed and, if the tumour was disseminated, the patient was excluded from the study. In 2008,\textsuperscript{30} 148 patients were identified, of which 90 completed the neoadjuvant
therapy and the LT; of these, 71 are alive and 19 died (8 due to tumour relapse), 19 are awaiting LT and 39 failed to meet neoadjuvant therapy due to disease progression. The 5-year survival rate of the group was 55% and the transplant survival rate was 71%. The success of this protocol is related to several factors: external and internal radiotherapy (useful for controlling wall invasion and peri-neural invasion); the strict selection of patients (all were stage I-II), unlike other series in which the stages III-IV exceed 40%; most patients were young; and finally, there was a significant percentage of primary sclerosing cholangitis (PSC) (65%). Neoadjuvant therapy was so effective that in many patients, no tumour was found in the explanted liver (although the pre-LT cytology was positive). In their series, prognostic factors were age >45 years, Ca 19/9 >100, the performance of a previous cholecystectomy, the presence of a residual tumour >2 cm, peri-neural invasion and the waiting time >100 days; hence the importance of living donor LT and implementation of an additional point system aside from the MELD system. This protocol has the disadvantage that it is associated with a higher percentage of late vascular complications and an increased need for using grafts, especially when using live donor LT. This increased difficulty associated with the significant fibrosis encountered during the transplant in relation to radiotherapy, although it does not affect patient or organ survival.

Other authors such as Sudan et al and Wu et al have partially reproduced these results. The last results reported 6 patients with PSC and cholangiocarcinoma, with a screening protocol similar to the patients of the Mayo Clinic who only received neoadjuvant radiotherapy for the LT with duodenopancreatectomy, of whom only one died of non-tumour causes and the other 5 remain alive after more than 5 years.

In the retrospective study, survival at 5 years in the LT group with neoadjuvant therapy was 82% compared to 21% in the group with TR without neoadjuvant therapy. However, the 2 groups were not homogeneous, as the age in the TH group was 48 years versus 63 years in the TR group and all were stage I-II, whereas in the TR group 14% had liver metastases, 39% had vascular invasion, 25% had positive lymph nodes in the portal vein, and 18% had peritoneal metastases. Furthermore, in the TR group only 38% had curative resections performed and 58% of transplant patients had a KT on a PSC compared to 8% of the resected patients.

To conclude, we agree with other authors that the LT, as indicated in many selected cases (unresectable tumours from intrahepatic biliary extension, non-disseminated, with the intervention of surgeons with experience in hepatic surgery), reach a higher survival rate than that from palliative treatment in patients with unresectable, non-disseminated KT. Neoadjuvant therapy protocols, proper staging, priority in the waiting lists for LT and LT with live donors may also contribute to the improvement of results.

**Conflict of interest**

The authors affirm that they have no conflicts of interest.

**REFERENCES**


